Gold and silver prices fell significantly in early U.S. trading due to a global bond selloff, a stronger U.S. dollar, and rising oil prices, as markets priced in a higher chance of a Federal Reserve rate hike in September. Spot gold dropped to around $4,370.80 an ounce, down 1.72%, and silver fell 2.73% to $64.60. The 10-year U.S. Treasury yield hit its highest since January 2025, reflecting expectations for tighter monetary policy amid inflation concerns. Upcoming U.S. labor market reports this week will be key in confirming or adjusting these rate hike expectations, influencing precious metals which are currently pressured by rising yields and a firm dollar rather than acting as safe havens. Geopolitical tensions in the Gulf are supporting oil prices and inflation risks, adding complexity to gold's outlook.
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...
Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...
Science Applications International Corporation (SAIC) saw its price target raised to $154 after reporting Q2 earnings of $3.01 per share, surpassing estimates by over 33%, and revenues of $1.88 billion, beating expectations by 7.52%. The company also...
UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...
